Skip to main content

Table 1 Overview of selected clinical trials of combined pharmacotherapy between mIDH1/2 inhibitors and other molecules

From: Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers

Drug combination Phase Number Enrolled Inclusion criteria Trail registration Status
Ivosidenib AZA Ib/II 131 Newly diagnosed AML NCT02677922 Active, not recruiting
venetoclax II 48 AML NCT03471260 Recruiting
FLAG Chemotherapy I 25 R/R AML NCT04250051 Not yet recruiting
CPX-351 II 30 AML/MDS NCT04493164 Recruiting
gemcitabine + cisplatin I 40 Cholangiocarcinoma NCT04088188 Recruiting
Decitabine/ ASTX727 + venetoclax Ib/II 84 R/R AML NCT04774393 Not yet recruiting
Enasidenib AZA II 50 R/R AML NCT03683433 Recruiting
AZA II 105 MDS NCT03383575 Recruiting
Ruxolitinib II 32 Myeloproliferative neoplasm NCT04281498 Not yet recruiting
CPX-351 II 18 Relapsed AML NCT03825796 Recruiting
venetoclax Ib/II 48 AML NCT04092179 Recruiting
Decitabine/ ASTX727 + venetoclax Ib/II 84 R/R AML NCT04774393 Not yet recruiting